| Field | Specification |
|---|---|
| Target | |
| Alternative names | ICI-50123 meglumine |
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C44H66N8O14S |
| SMILES | |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
Pentagastrin meglumine, also known as ICI-50123 meglumine, is a potent, selective agonist of the cholecystokinin B (CCKB) receptor, with an EC50 value of 11 nM. It enhances gastric mucosal defense mechanisms against acid and protects the gastric mucosa from experimental injury[1][2]. It has the molecular formula C44H66N8O14S (MW 963.11).
Physical & Chemical Properties
| CAS Number | 57448-84-7 |
|---|---|
| Molecular Formula | C44H66N8O14S |
| Molecular Weight | 963.11 g/mol |
| SMILES | O=C(N[C@@H](CCSC)C(N[C@@H](CC(O)=O)C(N[C@H](C(N)=O)CC1=CC=CC=C1)=O)=O)[C@@H](NC(CCNC(OC(C)(C)C)=O)=O)CC2=CNC3=C2C=CC=C3.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)CNC |
| Target | CCKBR |
| Signaling Pathway | GPCR/G Protein; Neuronal Signaling |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with your institution's chemical hygiene plan.
In Vitro
Pentagastrin meglumine (0.1-100 μM; GH3-cells) raises intracellular Ca2+ in a dose-dependent manner, up to a maximal 2.77-fold increase[1]. Pentagastrin meglumine (0.1-100 μM; GH3-cells) binds to GH3 cells in a dose-dependent manner[1].
In Vivo
Pentagastrin meglumine (80 μg/kg/h; intravenous infusion) protects the rat gastric mucosa against acidified aspirin injury[2].
| Animal Model | Male Sprague-Dawley rats[2] |
|---|---|
| Dosage | 80 μg/kg/h |
| Administration | Intravenous injection |
| Result | Protected rat gastric mucosa from acidified aspirin injury. Induced a hyperaemic response to luminal acid challenge, increased mucus gel thickness, and elevated pHi during acid challenge. |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
An Integrated Computational and Experimental Approach to Identifying Inhibitors for SARS-CoV-2 3CL Protease. Front Mol Biosci 2021 May 17:8:661424. PMID: 34079818
